I believe there was an analyst downgrade from Forsyth Barr which is probably the main reason. I don't have access to the article to see what their rationale is though.
FDA Approval, page-252
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.62 |
Change
-0.025(0.38%) |
Mkt cap ! $4.785B | |||
| Open | High | Low | Value | Volume |
| $6.61 | $6.66 | $6.58 | $7.890M | 1.192M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 19265 | $6.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.62 | 30577 | 16 |
View Market Depth
| Last trade - 13.46pm 20/06/2024 (20 minute delay) ? |
| A2M (ASX) Chart |